Graviton BioScience key facts
as of Oct 2026- Developer of clinical-stage drugs designed for the treatment of autoimmune, cancer, and other serious diseases.
- Graviton BioScience is valued at approximately $264.0M as of Oct 2026, set at its early-stage round, Feb 2024; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $93.3M across 4 recorded rounds; the latest was Early Stage VC ($25.0M) in Jan 2024.
- Notable investors include Cormorant Asset Management, Innova Capital Partners, Deep Future, Enavate Sciences, Ovid Therapeutics — 6 tracked in total.
- Graviton BioScience has filed 4 Form Ds with the SEC since 2021, most recently Feb 2024 ($25.0M sold to 1 investors).
- Status: Privately Held (backing).
Valued at $264.0M at its early-stage round, Feb 2024. Nothing has traded since.
- ·Watch Graviton BioScience: the Monday email on marks, rounds and moves
Graviton BioScience funding rounds
4 roundsWho backs Graviton BioScience
6Graviton BioScience valuation
Graviton BioScience was valued at $264 million at its early-stage round in Feb 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Graviton BioScience raised?
Graviton BioScience has raised $93.3 million across 4 recorded rounds since 2021. The largest was a $39.8 million early-stage round in Dec 2022; the most recent was a $25 million early-stage round in Jan 2024.
Graviton BioScience has filed 4 Form Ds with the SEC since 2021, most recently in Feb 2024 ($25 million sold to 1 investor).
Graviton BioScience investors
6 investors are on record for Graviton BioScience, including Cormorant Asset Management, Innova Capital Partners, Deep Future and Enavate Sciences. The early-stage round in Jan 2024 drew 1 investor.
About Graviton BioScience
Developer of clinical-stage drugs designed for the treatment of autoimmune, cancer, and other serious diseases. The company platform is dedicated to engineering and developing therapeutics for treating CNS, autoimmune, fibrotic, and other serious diseases, where its other therapeutic compounds play a pivotal role in pathology and offer drug candidates targeting rho-associated protein kinase, a key mediator of cellular contractility and fibrosis, enabling patients to potentially access groundbreaking treatments for a range of debilitating diseases.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 43
- Website
- gravitoncorp.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.